In patients with chronic viral hepatitis B, if the hepatitis B DNA is less than 100 IU/mL, it is considered that there is no viral replication at this time. Patients should continue to be monitored and should be rechecked every six months or a year for hepatitis B triple system, hepatitis B DNA and liver function to see if the virus is replicating. If the virus is replicating and there is an increase in glutamic and glutamic aminotransferase, antiviral therapy should be actively considered. You can consider oral medication or interferon injections. If a patient’s hepatitis B system suggests a major triple-positive, the patient is considered to have viral replication at this time, and a blood test for hepatitis B DNA suggests that the patient has viral replication, and the patient should consider active antiviral treatment at this time. If the hepatitis B DNA is less than 100 IU/mL and the liver function is normal, the patient needs to pay attention to rest, do not stay up late, do not strain, do not drink alcohol can. If the hepatitis B DNA is more than 100 IU/mL or 500 IU/mL, active antiviral treatment should be considered. In addition, patients should regularly review the upper abdominal ultrasound and gastroscopy to see if there is hypersplenism and the possibility of esophageal varices in the fundus of the stomach.